Form 4: Emergent BioSolutions Executive Sells Shares

Richard S. Lindahl, EVP and CFO of Emergent BioSolutions Inc., reported a transaction involving the withholding of shares to cover taxes related to restricted stock units.

Summary

• Richard S. Lindahl, Executive Vice President and Chief Financial Officer of Emergent BioSolutions Inc. (EBS), engaged in a transaction on June 8, 2026.
• This transaction involved the withholding of 3,964 shares of common stock.
• These shares were withheld to cover tax obligations arising from the vesting and settlement of restricted stock units.
• Following this transaction, Mr. Lindahl beneficially owns 374,083 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine tax settlement transaction for an executive rather than a strategic decision to buy or sell shares based on company performance or outlook.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Management Comments

• "Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units."

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive stock dealings. This specific transaction relates to the common practice of using company stock to cover tax liabilities upon vesting of equity awards.

Stakeholder Impact

• Shareholders: Increased transparency regarding executive compensation and stock ownership. The transaction itself does not represent a change in beneficial ownership intent but rather a tax settlement.
• Employees: Highlights the mechanics of equity compensation and its tax implications for executives.
• Management: Standard reporting requirement for executive compensation events.

Key Dates

Keywords

Emergent BioSolutions, EBS, Form 4, Insider Transaction, Stock Withholding, Restricted Stock Units, Executive Compensation, SEC Filing